Syntax II and Syntax III trials: what is the take home message for surgeons? The Syntax III trial

Daniele Andreini, Saima Mushtaq, Carlos Collet, Gianluca Pontone, Mauro Pepi, Laurent Macron, Giorgia Bonalumi, Cristina Ferrari, Maurizio Roberto, Yosuke Miyazaki, Laura Cavallotti, Yoshinobu Onuma, Paolo Olivares, Francesco Maisano, Antonio L. Bartorelli, Patrick W. Serruys

Journal of cardiovascular computed tomography

Article2018

TCT-322 Agreement between coronary CTA and conventional angiography on the SYNTAX score tertiles stratified by anatomical complexity in the SYNTAX III Revolution trial

Carlos Collet, Daniele Andreini, Ulf Teichgräber, Torsten Doenst, Holger H. Sigusch, Jasmina Alibegovic, Robert Manka, André Plass, Ahmed Ouda, Dries Belsack, Jens Czapla, Stijn Lochy, Danny Schoors, Yoshinobu Onuma, Patrick W. Serruys, Antonio L. Bartorelli

Journal of the American College of Cardiology

Syntax II and Syntax III trials: what is the take home message for surgeons? The Syntax III trial

Abstract

Discussion(0)

Related publications

Syntax II and Syntax III trials: what is the take home message for surgeons? Lessons learned from the 2 year results of Syntax II

SYNTAX II and SYNTAX III trials: what is the take home message for surgeons?

TCT-587 What if current generation drug-eluting stents were used in the SYNTAX trial? Analysis of the COMPARE and SYNTAX trials 5 year follow-up

Assessment Of Heart Team’S Treatment Decision Variability: Insights From The Syntax III Revolution Trial.

TCT-322 Agreement between coronary CTA and conventional angiography on the SYNTAX score tertiles stratified by anatomical complexity in the SYNTAX III Revolution trial